RecruitingNot Applicable

ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)

United States150 participantsStarted 2021-04-26

Plain-language summary

This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.

Who can participate

Age range12 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Documented diagnosis of AHP, per physician's determination Exclusion Criteria: * Currently enrolled in a clinical trial for any investigational agent

What they're measuring

Incidence of Selected Events of Interest in AHP Patients

Timeframe: Up to 6 years

Trial details

NCT IDNCT04883905

SponsorAlnylam Pharmaceuticals

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2027-04-01

Contact for this trial

Alnylam Clinical Trial Information Line

1-877-ALNYLAM clinicaltrials@alnylam.com

View on ClinicalTrials.gov More Acute Hepatic Porphyria trials